Key Quantitative Figures
Standalone Financial Results (Quarter ended June 30, 2026):
- Revenue from operations: ₹1,805.83 lakhs
- Other Income: ₹645.77 lakhs
- Total Income: ₹2,451.60 lakhs
- Total Expenses: ₹1,587.08 lakhs
- Profit Before Tax: ₹864.53 lakhs
- Tax Expense: ₹140.65 lakhs (₹125.00 lakhs current tax + ₹15.64 lakhs deferred tax)
- Net Profit for the period: ₹723.88 lakhs
- Basic & Diluted EPS: ₹12.93
- Equity Share Capital: ₹560.06 lakhs
Consolidated Financial Results (Quarter ended June 30, 2026):
- Revenue from operations: ₹1,812.89 lakhs
- Other Income: ₹656.79 lakhs
- Total Income: ₹2,469.68 lakhs
- Total Expenses: ₹1,609.26 lakhs
- Profit Before Share of Profit of Associate: ₹860.42 lakhs
- Share of Profit of Associate: ₹27.30 lakhs
- Profit Before Tax: ₹887.72 lakhs
- Tax Expense: ₹140.64 lakhs (₹125.00 lakhs current tax + ₹15.64 lakhs deferred tax)
- Net Profit for the period: ₹747.08 lakhs
- Basic & Diluted EPS: ₹13.34
Dates of Action
- Board Meeting Date: August 12, 2026
- Meeting Time: 5:00 PM to 6:00 PM
- Quarter Ended: June 30, 2026
- Financial Results Approval Date: August 12, 2026
Parties Involved
- Statutory Auditors: R. K. Doshi & Co. LLP (FRN: 102745W/W100242)
- Subsidiaries: Fernway Technologies Limited, Stellent Chemicals Industries Limited
- Associate: McGean India Chemicals Private Limited (Step-down associate of Stellent Chemicals)
- Former Subsidiary: Dinesh Remedies Limited (disposed on September 3, 2025)
- Regulatory Authorities: BSE Limited, SEBI, NCLT
Corporate Governance Updates
The Board constituted a Committee of Independent Directors comprising:
- Mr. Strivinder Singh Chawla
- Mr. Sameer Khera
- Ms. Reshma Patel
- Mrs. Tejal Amin
The committee is authorized to discharge functions and exercise powers as required under the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable regulations.
Demerger and Restructuring Update
The Company disclosed to BSE Ltd. on April 29, 2026, that promoters executed a Family Settlement Agreement (FSA) on April 29, 2026, between Shri Bharatbhai Patel & Shri Aditya Patel (BUP Family) and Shri Nimishbhai Patel & Shri Nishank Patel (NUP Family).
Although the Company was not a party to the FSA, the Board noted the disclosure and granted in-principle approval for demerger of the Company's FELT business into a separate legal entity, subject to NCLT and other approvals. Until the proposed demerger, the Board approved segregation of the FELT and Residual Businesses and assigned directors for separate oversight of each vertical.
Subsidiary and Associate Information
The consolidated financial results include:
- Two subsidiaries (Fernway Technologies Limited and Stellent Chemicals Industries Limited) with total revenues of ₹45.38 lakhs and net profit of ₹23.20 lakhs for the quarter
- One associate (McGean India Chemicals Private Limited) with Group's share of profit including other comprehensive income of ₹27.30 lakhs for the quarter
Discontinued Operations
The Company disposed of its entire investment in equity and preference shares of Dinesh Remedies Limited on September 3, 2025. The subsidiary has been classified as discontinued operations, with a loss of ₹57.14 lakhs for the quarter ended June 30, 2025, and ₹46.72 lakhs for the year ended March 31, 2026.
Auditor's Review
The statutory auditors, R. K. Doshi & Co. LLP, conducted a limited review of both standalone and consolidated financial results and issued an unmodified review report, stating that nothing has come to their attention that causes them to believe the statements contain any material misstatement.
Business Segment
The Company has only one reportable primary business segment as per Ind AS 108 - "Textiles"